EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Enavogliflozin, an SGLT2 Inhibitor, Improves Nonalcoholic Steatohepatitis Induced by High-Fat, High-Cholesterol Diet

Phuc Thi Minh Pham, Giang Nguyen, So Young Park, Thuy Linh Lai, Dae-Hee Choi, Jeana Hong, Seon Mee Kang, Eun-Hee Cho

Diabetes & Metabolism Journal · 2026

DOI: 10.4093/dmj.2024.0259 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes & Metabolism Journal, 2026. Verfasst von Phuc Thi Minh Pham und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Sodium-Glucose Transporter 2 Inhibitors, Diet, High-Fat, Benzhydryl Compounds. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Daewoong Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nonalcoholic fatty liver disease, a progressive condition caused by the accumulation of fat in the liver, begins with simple steatosis and can potentially progress to metabolic dysfunction-associated steatohepatitis (MASH) in the presence of inflammation and fibrosis, ultimately leading to cirrhosis or hepatocellular carcinoma. Increasing evidence indicates that sodiumglucose cotransporter 2 (SGLT2) inhibitors effectively alleviate MASH in mouse models. However, there is a lack of research on the effects of enavogliflozin on liver disease. In the present study, we investigated the effects of SGLT2 inhibitors on MASH induced by a high-fat, high-cholesterol (HFHC) diet in mice.

Methods

Male C57BL/6 mice were fed a normal chow diet, HFHC diet, or HFHC diet with enavogliflozin for 12 weeks. LX-2 and HepG2 cells were treated with enavogliflozin in the presence of various pathological stimuli.

Results

The HFHC diet induced excessive hepatic lipid accumulation, inflammation, and severe fibrosis. Administration of enavogliflozin not only ameliorated hepatic steatosis and fibrotic conditions but also suppressed the production of inflammatory cytokines. Positive outcomes were also observed in in vitro experiments, where enavogliflozin demonstrated the ability to impede the activation of hepatic stellate cells and alleviate lipid accumulation in hepatocytes. The potential pathway through which enavogliflozin attenuated liver fibrosis development may be associated with the transforming growth factor β1/Smad signaling pathway.

Conclusion

Our results suggest that enavogliflozin is effective in a mouse model of MASH by attenuating hepatic steatosis, suppressing inflammation, and improving liver fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseSodium-Glucose Transporter 2 InhibitorsDiet, High-FatBenzhydryl CompoundsAnimalsMaleMiceMice, Inbred C57BLHumansHep G2 CellsLiverCholesterol, DietaryBenzofuransSorbitol

Stichwörter der Autor:innen

Cholesterol, dietaryDiet, high-fatEnavogliflozinLiver cirrhosisNon-alcoholic fatty liver disease

Substanzen

Sodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsCholesterol, Dietary1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitolEnavogliflozinBenzofuransSorbitol

Autor:innen und Institutionen

  • Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea.
  • Department of Pediatrics, Kangwon National University School of Medicine, Chuncheon, Korea.

Förderung

  • Daewoong Pharmaceuticals

Zitieren

APA

Pham, P. T. M., Nguyen, G., Park, S. Y., Lai, T. L., Choi, D. H., Hong, J., Kang, S. M., & Cho, E. H. (2026). Enavogliflozin, an SGLT2 Inhibitor, Improves Nonalcoholic Steatohepatitis Induced by High-Fat, High-Cholesterol Diet. Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2024.0259

Vancouver

Pham PTM, Nguyen G, Park SY, Lai TL, Choi DH, Hong J, et al. Enavogliflozin, an SGLT2 Inhibitor, Improves Nonalcoholic Steatohepatitis Induced by High-Fat, High-Cholesterol Diet. Diabetes & Metabolism Journal. 2026. doi:10.4093/dmj.2024.0259

BibTeX
@article{Pham2026,
  author = {Pham, Phuc Thi Minh and Nguyen, Giang and Park, So Young and Lai, Thuy Linh and Choi, Dae-Hee and Hong, Jeana and Kang, Seon Mee and Cho, Eun-Hee},
  title = {Enavogliflozin, an SGLT2 Inhibitor, Improves Nonalcoholic Steatohepatitis Induced by High-Fat, High-Cholesterol Diet},
  journal = {Diabetes & Metabolism Journal},
  year = {2026},
  doi = {10.4093/dmj.2024.0259}
}
Kostenlos starten →